linjc16/ctgov huggingface dataset:
PreCoCa - Prehospital Cooling With Cool-Caps

Study Overview
=================
Brief Summary
-----------------
This study shall investigate the feasibility of the use of cool-caps in the preclinical setting in patients with successful primary cardio-pulmonary resuscitation Hypothesis: cool-caps are efficient and feasible to use in the preclinical setting in patients after successful CPR.

Conditions
-----------------
Heart Arrest

Intervention / Treatment
-----------------
* Device: Application of cool cap after primary successful CPR


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: All patients with primary successful CPR Exclusion Criteria: Age < 18 Pregnancy Severe bleeding or severe trauma Body core temperature < 34 degrees celsius

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Intervention/Treatment |
| --- |
|Device: Application of cool cap after primary successful CPR|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Body core temperature at hospital/ ICU admission |  | 1 day | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
primary successful cardio-pulmonary resuscitation, pre-hospital setting
Hyperbaric Oxygen - a New Treatment Modality in Patients With Radiation Damaged Salivary Gland Tissue

Study Overview
=================
Brief Summary
-----------------
Randomized clinical trial regarding the effect of hyperbaric oxygen on late radiation tissue injury to salivary gland tissue.

Official Title
-----------------
Hyperbaric Oxygen - a New Treatment Modality in Patients With Radiation Damaged Salivary Gland Tissue.

Conditions
-----------------
Late Effect of Radiation

Intervention / Treatment
-----------------
* Procedure: Hyperbaric oxygen


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria Head and neck cancer with planned radiation therapy Age > 18 years Exclusion Criteria: Surgical treatment of head and neck cancer Salivary gland disease Severe claustrophobia Pregnancy or lactation (fertile women must use safe contraceptives) Uncontrolled hypertension (> 220/110) Epilepsy Lack of ability to equalize inner ear pressure Pneumothorax Thoracic surgery within one month before HBO treatment Abuse of alcohol, drugs or narcotics Exposed titanium surfaces or defect titanium in the oral cavity Previous HBO treatment

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Supportive Care
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: HBO<br>30 90-minute hyperbaric oxygen sessions at 2.4 atm. | Procedure: Hyperbaric oxygen<br>* Inhalation of 100% oxygen for 90 minutes<br>|
| No Intervention: No HBO<br>No intervention. No hyperbaric oxygen is administered. Otherwise, the patient will follow the examination program. | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Salivation rate |  | 6 months | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Quality of life |  | 6 months | 
| Xerostomia | Xerostomia questionnaire | 6 months | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
radiation sequelae, hyperbaric oxygen
Comparison of the Incidence of Dyskinesia in Parkinson's Disease Who Were Treated With Amantadine or Dopamine Agonist

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to compare the onset time and severity of dyskinesia in amantadine or Dopamine agonist initial treated groups in Parkinson's disease.

Detailed Description
-----------------
Dopamine agonist can delay the risk of dyskinesia by initiating treatment rather than levodopa. Amantadine is typical antidyskinetic drug. There is no data about comparison of risk of dyskinesia in amantadine and dopamine agonist by initiating treatment. Prospective , randomized, open label study compare the onset time and severity of dyskinesia between groups randomized assigned order of amantadine and dopamine agonist

Official Title
-----------------
A 10-year Observational Study of the Incidence of Dyskinesia in Patients With Early Parkinson's Disease Who Were Treated With Amantadine or Dopamine Agonist

Conditions
-----------------
Parkinson's Disease

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: 30<age<60 IPD H & Y<3 Exclusion Criteria: previous dopaminergic medication history dyskinesia Parkinson plus clinically significant or unstable medical or surgical condition

Ages Eligible for Study
-----------------
Minimum Age: 30 Years
Maximum Age: 60 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Group A-1<br>study enroll number 3n+1 (N=0,1,2...) initial treatment- amantadine add levodopa when the patient become to need further treatment. | |
| Group A-2<br>study enroll number 3n+2 (N=0,1,2...) initial treatment: amantadine add dopamine agonist when the patient become to need further treatment. | |
| Group B<br>study enroll number 3n+3 (N=0,1,2...) initial treatment: dopamine agonist add levodopa when the patient become to need further treatment. but cannot use amantadine | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| dyskinesia onset | observe duration of onset of dyskinesia from initial treatment observe until 10 years | up to 10 years from the start of durg (Amantadine or dopaimine agonsit) | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| UPDRS, severity of dyskinesia between groups | observe duration of onset of dyskinesia from initial treatment observe until 10 years compare the UPDRS and severity of dyskinesia between groups | observe duration of onset of dyskinesia from initial treatment | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Parkinson's disease
Frequency of Residual Neuromuscular Blockade in the Pediatric Population

Study Overview
=================
Brief Summary
-----------------
This study is designed to investigate the frequency of Residual Neuromuscular Blockade (RNMB) in the pediatric population.

Detailed Description
-----------------
The proposed study will be the first to investigate the incidence of residual postoperative neuromuscular blockade in the pediatric patient following the intraoperative use of NMBA's. If there is significant residual blockade present, it may be that these effects will lead to postoperative respiratory complications including hypoxemia, atelectasis, and prolonged oxygen requirement resulting in a prolonged stay in the post-anesthesia care unit.

Conditions
-----------------
Neuromuscular Blockade

Intervention / Treatment
-----------------
* Procedure: Neuromuscular blockade


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Age less than 18 years. Surgery requiring the administration of neuromuscular blocking, agents with planned extubation in the postoperative care unit (PACU). Exclusion Criteria: Neuromuscular diseases which may prolong the duration of NMBA's or exaggerate the effects of residual blockade. The need for postoperative mechanical ventilation. Direct admission to the Pediatric ICU, NICU or CTICU.

Ages Eligible for Study
-----------------
Maximum Age: 17 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Neuromuscular blockade<br> | Procedure: Neuromuscular blockade<br> <br> |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| train-of-four (TOF) ratio | TOF ratio shows the residual of neuromuscular agents. | 1 day |
Risedronate for the Prevention of Osteoporosis in People With Spinal Cord Injury.

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to find out if Risedronate works to prevent osteoporosis after spinal cord injury.

Official Title
-----------------
Risedronate for Prevention of Osteoporosis After Spinal Cord Injury

Conditions
-----------------
Acute Spinal Cord Injury.

Intervention / Treatment
-----------------
* Drug: Risedronate


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Traumatic spinal cord injury less than 100 days. Must be able to swallow tablets and sit upright. Exclusion Criteria: Bilateral knee flexion contractures. Pregnant, lactating or post-menopausal females. Paget's disease, osteomalacia, steroid induced bone loss, untreated thyroid disease, iritis, uveitis, pancreatitis, gastritis, peptic ulcer or cholecystitis. Treatment in the last year with calcitonin, fluoride or anabolic steroid. Concurrent treatment with prednisone.

Ages Eligible for Study
-----------------
Minimum Age: 16 Years
Maximum Age: 60 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Prevention
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double


Arms and Interventions

| Intervention/Treatment |
| --- |
|Drug: Risedronate|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Change in bone mineral density of the distal femur and proximal tibia between baseline, 12-months and 24-months. |  |  | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Change in bone mineral density of the total body, spine and femoral neck between baseline, 12-months and 24-months. |  |  | 
| Change in biochemical markers of bone turnover between baseline, 12-months and 24-months. |  |  | 
| Frequency and severity of adverse events. |  |  | 
| Quality of life. |  |  | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Osteoporosis, Spinal Cord Injury
Study on the Incidence of Febrile Episodes During Stem Cells Collection After Chemotherapy in Patients With Multiple Myeloma

Study Overview
=================
Brief Summary
-----------------
To evaluate the difference in the incidence of febrile episodes in patients undergoing stem cells mobilization with chemotherapy and filgrastim versus chemotherapy and lenograstim. A febrile episode will be considered as: body temperature > 38°C for two measurements in the 24 hours with an interval of 6 hours at least between the two measurements.

Official Title
-----------------
Study on the Incidence of Febrile Episodes During Stem Cells Collection After Chemotherapy in Patients With Multiple Myeloma

Conditions
-----------------
G-CSF, Multiple Myeloma, Febrile Episode, Filgrastim, Leograstim

Intervention / Treatment
-----------------
* Drug: filgrastim
* Drug: lenograstim


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Age > 18 and < 70 years Diagnosis of multiple myeloma ECOG < 2 to be evaluated at baseline, after the induction chemotherapy Indication to the mobilization with high dose cyclophosphamide chemotherapy Normal blood counts: neutrophils > 1500/μl; platelets > 100.000/μl; hemoglobin > 10 g/dl. Liver and renal function: SGOT/AST, SGPT/ALT; bilirubin < 1.5 times the upper limit of the normal ranges; creatinine < 2 times the upper limit of the normal ranges. Interval from previous induction chemotherapy to high dose chemotherapy between 30 and 60 days ECG e/o Echocardiogram within age related normal range Negative HCV and HbsAg Must be willing and able to fill in the patient's diary Written informed consent Exclusion Criteria: Documented and/or suspected infections Uncontrolled concurrent illness Documented cardiac dysfunction

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 70 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Prevention
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Active Comparator: filgrastim<br>patients mobilized with filgrastim | Drug: filgrastim<br>* subcutaneous filgrastim administration<br>|
| Active Comparator: lenograstim<br>patients mobilized with lenograstim | Drug: lenograstim<br>* subcutaneous lenograstim administration<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| febrile episode |  | 30 days | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Documented infectious episodes Collection efficiency (CD34+ cells/kilo) Mobilization days Safety |  | 30 days |
Evaluation of Shear Wave Elastography Reproducibility in Achilles Tendons and Plantar Fascia

Study Overview
=================
Brief Summary
-----------------
Achilles tendon plays a significant role in walking and sporting activities, particularly through ankle joint and lower limbs stability. Ultrasound imaging can be the first-line examination of choice for patients suspected of having Achilles tendon injury, which is more and more frequent. Nowadays, ultrasound elastography can be used to evaluate the viscoelasticity properties of Achilles tendon, however little is known about the reproducibility of the technique. This study aims to evaluate the reproducibility of supersonic shear imaging SWE™ Young's modulus measurements of shear wave velocity (m/s) in Achilles tendon and plantar fascia.

Official Title
-----------------
Evaluation of the Reproducibility of Young's Modulus and Shear Wave Velocity Measurements With SWE™ in Achilles Tendons and Plantar Fascia

Conditions
-----------------
Achilles Tendon, Plantar Fascia

Intervention / Treatment
-----------------
* Other: Supersonic ShearWave Elastography


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Volunteers with normal Achilles tendon: Normal adult aged over 18 years old; Without lower limb malformation; With no symptoms of Achilles tendon lesion and no negative results of routine ultrasound examination for a possible tendinopathy. Exclusion Criteria: Subjects who failed to meet all inclusion criteria were will be automatically excluded; Subjects who did will not wish or could will not sign the informed consent in person. Volunteers with abnormal Achilles tendon for any of these reasons: Lower limb malformation; Achilles tendon pain, Achilles tendon disease, surgical history of Achilles tendon surgery, morphologic abnormalities of Achilles tendon ( gray-scale/color Doppler/MRI/plain film); Suffer from systemic, metabolic and endocrine diseases, including but not limited to, diabetes, familial hyperlipidemia (FH), systemic lupus erythematosus (SLE), gout, ankylosing spondylitis, hyperthyroidism, chronic renal failure, etc. Pregnant women; Apply Ongoing hormone hormonal therapy; Athletes

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 100 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Other: Supersonic ShearWave Elastography|ShearWave Elastography (SWE) is part of routine ultrasound examination|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Intra- and inter-operator reproducibility | Intraclass Correlation Coefficient | Baseline | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Elastography, Musculoskeletal System
Protection Against Allergy: Study in Rural Environment - Part IV

Study Overview
=================
Brief Summary
-----------------
PASTURE is a birth cohort of children born to farm and non-farm women from rural areas across Europe. Five study centres Austria, Germany, Switzerland, France and Finland enrolled 1133 children (farmers in about half of the children) to study the origins of asthma and atopy and to develop potential preventive strategies. Previous results show a protective effect of farm exposure on allergic risk by livestock contacts and microbial exposures and by raw cow milk consumption in early age. PASTURE Part IV is the 10-year follow up of this birth cohort. The primary objective is to characterize the allergic phenotype between 6 and 10 years old (asthma and allergic rhinitis) and to explain how early age exposures and particularly milk products consumption contribute in the process of allergic illness in childhood. A focus on the characterization of the protective biologically active components in raw milk and identification of immunological mechanisms are involved.

Conditions
-----------------
Asthma, Atopy

Intervention / Treatment
-----------------
* Other: blood sampling, skin prick tests, assesment of atopic dermatitis, questionnaires


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: PATURE IV is a birth cohort. All children enrolled at the beginning and who still agree to participate will be included at 10-year follow-up. Exclusion Criteria: -

Ages Eligible for Study
-----------------
Minimum Age: 10 Years
Maximum Age: 11 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Prevention
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Other: single arm study<br> | Other: blood sampling, skin prick tests, assesment of atopic dermatitis, questionnaires<br> <br> |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Asthma |  | 10 years old | 
| Rhinitis |  | 10 years old | 
| Atopic Dermatitis |  | 10 years old | 
| Food Allergy |  | 10 years old | 
| Skin prick tests |  | 10 years old | 
| Specific Immunoglobulin E (IgEs) |  | 10 years old | 
| Blood cytokine profiles |  | 10 years old | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
farm children, non-farm children
Relationship of Facial Pattern With Bruxism

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to determine if the facial pattern is related to the degree of bruxism because the muscles of mastication are the factors of force to the wear of the teeth.

Official Title
-----------------
Relationship of Facial Pattern With Bruxism

Conditions
-----------------
Bruxism

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Both genders Age 18 to 60 years Case studies to understand orthodontic intraoral photographs of the upper and lower dental arches, and models of lateral skull radiography for orthodontic Cases with any facial biotype development. Exclusion Criteria: Totally toothless people Partially toothless the posterior (include both molars and premolars). Dawn Syndrome,alzheimer , partial or bilateral facial palsy, autism, which manifest with bruxism Some other syndrome which alters the pattern of facial development as Pierre Robin,crouzon

Ages Eligible for Study
-----------------
Minimum Age: 12 Years
Maximum Age: 60 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
facial patterns, bruxism, masticatory muscles
The Effects of a Specific Exercise Program on Subjects With Cervicogenic Headache

Study Overview
=================
Brief Summary
-----------------
This study explores with the use of MSK Ultrasound imaging if the obliquus capitis minor and the rectus capitis major can be contracted with specific exercises.

Detailed Description
-----------------
This study explores if a subject with the neck in full maximal flexion is able to selective contract the the obliquus capitis minor and the rectus capitis major by head extension and rotation while maintaining the spine position. MSK Ultrasound imaging will be used to measure changes both in length and width.

Official Title
-----------------
The Effects of a Specific Exercise Program on Subjects With Cervicogenic Headache

Conditions
-----------------
Cervicogenic Headache

Intervention / Treatment
-----------------
* Other: Head extension and rotation movement


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: No history of surgery, No current neck pain, Being able to move the neck actively, being able to read English, between ages 18-65 Exclusion Criteria: Neck pain, History of surgery, unable to move the head into extension, outside age requirements, unable to read English

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 65 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Intervention Model: Single Group Assignment
Interventional Model Description: One group design
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Other: neck extension group<br>Neck extension group | Other: Head extension and rotation movement<br>* Active exercise of the head<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| MSK US image | Assessment of change in width and length of target muscles | The change in muscle length and diameter will be measured during head movement | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Cervicogenic headache, MSK Ultrasound, Obliquus capitis minor, Rectus capitis major, Exercise